About Edgewise Therapeutics
Edgewise Therapeutics (NASDAQ:EWTX) is a pioneering firm focused on leveraging precision medicine to address a range of serious musculoskeletal diseases with a primary focus on Duchenne and Becker muscular dystrophies. At the heart of its operations, Edgewise Therapeutics is deeply involved in discovering, developing, and deploying transformative therapies designed to improve the lives of individuals grappling with these challenging conditions. Through a robust pipeline of therapeutic candidates, the company aims to halt muscle damage, reduce the severity of symptoms, and ultimately enhance quality of life. With a steadfast commitment to innovation and patient health, Edgewise Therapeutics sets the bar in redefining treatment standards for musculoskeletal diseases, underpinned by rigorous research, strategic collaborations, and a patient-centric approach.
Snapshot
Operations
Products and/or services of Edgewise Therapeutics
- Development of a precision medicine for the treatment of Duchenne Muscular Dystrophy, focusing on preserving muscle function.
- A novel therapeutic approach targeting Becker Muscular Dystrophy to slow disease progression and improve patient quality of life.
- Advancing a pipeline of small molecule therapies aimed at limb-girdle muscular dystrophy, designed to enhance muscle strength.
- Research into targeted treatments for facioscapulohumeral muscular dystrophy, emphasizing muscle protection and function maintenance.
- Creating innovative therapies for the management of myotonic dystrophy, focusing on reducing muscle wasting and improving mobility.
- Development of cutting-edge, non-invasive diagnostics for early detection and monitoring of muscular dystrophies to optimize treatment outcomes.
Edgewise Therapeutics executive team
- Dr. Kevin Koch Ph.D.President, CEO & Director
- Dr. Behrad Derakhshan Ph.D.Chief Operating Officer
- Dr. Joanne M. Donovan M.D., Ph.D.Chief Medical Officer
- Dr. Alan J. Russell Ph.D.Co-Founder, Chief Scientific Officer & Director
- Mr. Michael P. NofiChief Financial Officer
- Mr. John R. Moore J.D.General Counsel
- Dr. Robert Blaustein M.D., Ph.D.Chief Development Officer